Business Context and Reporting Period
This Form 8-K is filed by Pro-Pharmaceuticals, Inc. (noted in metadata as Galectin Therapeutics Inc.) for the reporting period of October 19, 2007. The filing discloses the entry into a material definitive agreement and the unregistered sale of equity securities in connection with a private placement.
Key Financial Metrics and Transaction Details
The company raised $25,000 through the sale of 25,000 Units to Mildred Christian, Ph.D., a member of the Board of Directors. The transaction was priced at $1.00 per Unit. Each Unit consists of:
- One share of Series A 12% Convertible Preferred Stock.
- One Common Stock Purchase Warrant with an exercise price of $1.50.
- One Common Stock Purchase Warrant with an exercise price of $2.00.
The Preferred Stock accrues interest at 12% per annum, payable in cash or common stock at the company's option. The filing does not provide broader financial metrics such as total revenue, net profit, operating cash flow, or aggregate debt levels.
Material Changes and Terms
The primary material change is the issuance of new equity securities. Key terms include:
- Warrant Exercise: Warrants are exercisable for cash beginning 181 days after issuance and expire on the fourth anniversary of the issue date.
- Conversion: Preferred Stock is convertible at the holder's option into one share of Common Stock. The company holds a mandatory conversion right if the Common Stock closing price exceeds $3.00 for 15 consecutive trading days and a registration statement is in effect.
- Registration Rights: The company agreed to file a registration statement with the SEC within six months of the offering's closing to register the resale of shares issuable upon conversion and warrant exercise.
Outlook, Risks, and Contingencies
The transaction was conducted under Section 4(2) of the Securities Act of 1933 as an exemption for sales to "accredited investors." The filing incorporates by reference the full text of the Securities Purchase Agreement, Registration Rights Agreement, and Warrants, noting that the summary is qualified by these documents. No specific forward-looking guidance or risk factors beyond standard securities law disclosures are detailed in this specific excerpt.
Investor Verification Checklist
- Verify the exact identity of the registrant (Pro-Pharmaceuticals, Inc. vs. Galectin Therapeutics Inc.) to ensure correct entity tracking.
- Confirm the status of the registration statement required to be filed within six months of the October 2007 closing.
- Review the full text of the Series A Preferred Stock Certificate of Designation for specific dividend payment dates and conversion mechanics.
- Assess the dilution impact of the 25,000 Units and the potential future issuance of shares upon warrant exercise.